Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News We’re Watching: Premom Data Privacy Settlement, Labcorp Owes $372m For Patent Violations, Elixir Stent Trial Success

Executive Summary

This week, the DC Attorney General announced a settlement with ovulation-tracking app Premom; a novel scoliosis treatment won FDA approval; research showed Fractyl Health’s Rejuva delivery system can deliver gene therapy directly to the pancreas; and BearCare recalled a thermometer over burn risks.

You may also be interested in...



News We’re Watching: MedRhythms App Gets FDA Clearance, Recalls For Megadyne And Draeger, Elixir Stent Trial Moves Ahead

This week, companies including MedRhythms, Allergan and Urotronic announced FDA clearances; Quest and Envision launched a prostate cancer test; and the FDA designated two recalls as class I.

News We’re Watching: May Health PCOS Treatment Shows Promise, Roche Adds Alzheimer’s Assays, Luciole Buys Spiegelberg

This week, May Health’s Ovarian Rebalancing showed promise as a treatment for polycystic ovarian syndrome; a trial of CathWorks’ FFRangio System launched; Roche introduced new assays for Alzheimer’s Disease; Early Health settled data breach allegations; and Boston Scientific added two new board members.

With Roe v. Wade In Rearview, What’s Next For Women’s Health?

Manufacturers of devices and apps focused on reproductive health are still feeling out the import of a recent US Supreme Court decision overturning the federal right to abortion. Some attorneys say the ramifications may be vast.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147933

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel